Fewer patients will be receiving the erythropoiesis-stimulating agents (ESAs) Procrit, Epogen, and Aranesp
June 2007
Fewer patients will be receiving the erythropoiesis-stimulating agents (ESAs) Procrit, Epogen, and Aranesp.
Chronic kidney disease. ESAs are associated with an increase in death and cardiovascular events when used to boost hemoglobin above 12 g/dL. These drugs can increase thrombosis risk.
Kidney guidelines will recommend aiming for lower hemoglobin targets in the range of 11 to 12 g/dL.
Practical advice for a better career, with unlimited access to CE
Pharmacy Technician's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 120+ CE courses, including the popular CE-in-the-Letter
- Helpful, in-depth Technician Tutorials
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote